HCONRES 42 is a symbolic congressional resolution recognizing the persistent wage gap between Black women and White, non-Hispanic men in the U.S. It highlights that Black women earn 66 cents for every dollar earned by White, non-Hispanic men working full-time year-round, with the gap taking over 200 years to close at current rates. The resolution emphasizes how this disparity - rooted in both racial and gender discrimination - impacts Black women’s ability to afford essentials like education, childcare, and housing. It does not create new laws or policies but formally acknowledges the issue on Black Women’s Equal Pay Day (July 10, 2025) and reaffirms support for equal pay.
This non-binding resolution recognizes climate change as a growing public health threat and urges the Department of Health and Human Services (HHS) to prioritize climate resilience in healthcare. It recommends specific actions, including reinstating the Office of Climate Change and Health Equity, directing funding toward underserved communities for infrastructure upgrades, establishing worker heat protection standards, and requiring annual progress reports on health equity outcomes. The resolution directly affects HHS agencies, healthcare providers (especially in rural, Tribal, and low-income areas), and workers facing climate-related health risks. It does not create new laws but calls for coordinated federal action to address climate-driven health impacts like heat-related illnesses, mental health strain, and disease spread.
HRES 575 is a symbolic resolution designating July 10th as "Journeyman Lineworkers Recognition Day." It honors lineworkers who face significant risks daily - working at heights near live wires and responding to disasters like hurricanes and wildfires. The resolution specifically references Henry Miller, an early leader of the International Brotherhood of Electrical Workers, who died on July 10, 1896, while troubleshooting an outage. It encourages the public to recognize these workers' contributions but does not create new laws or allocate funding.
S 2239, the "Improving Access to Prenatal Care for Military Families Act," allows pregnant service members and their dependents to enroll in TRICARE Select health coverage immediately upon pregnancy, treating it as a qualifying event (like a job change or separation) rather than requiring them to wait for other life events. The bill establishes a 5-year pilot program starting within 180 days of enactment, requiring the Secretary of Defense to implement this change and report annually to Congress on enrollment trends. These reports must detail enrollment changes by month and by specific circumstances, such as separation from duty or pregnancy itself. The bill directly affects military families seeking timely prenatal care under TRICARE Select, aiming to streamline access without altering existing eligibility rules.
The PBM Reform Act of 2025 aims to increase transparency and fairness in pharmacy benefit manager (PBM) operations within Medicare Part D and Medicaid programs. The bill requires Medicare Part D plans to allow any pharmacy meeting standard terms to join their networks, establishes "essential retail pharmacies" in underserved areas (with limited pharmacy access), and mandates detailed reporting on drug pricing, rebates, and reimbursement rates. It creates a process for pharmacies to report PBM violations of reasonable contract terms and prohibits "spread pricing" in Medicaid, where PBMs retain the difference between what they pay pharmacies and what they charge plans. These provisions aim to improve pharmacy access for Medicare beneficiaries and ensure fairer reimbursement practices for pharmacies.
SRES 312 is a non-binding Senate resolution designating June 2025 as "LGBTQ Pride Month" to honor the LGBTQ community's historical struggles and contributions to U.S. society. The resolution expresses symbolic support for LGBTQ rights and highlights ongoing challenges like discrimination in housing, employment, and healthcare, without creating new laws or policies. It serves as a formal acknowledgment by the Senate to promote awareness of LGBTQ history and advocacy, but has no legal effect on government actions or individual rights. The resolution was introduced by multiple senators and includes a preamble detailing key milestones in LGBTQ equality efforts.
This bill restores a rule limiting tax deductions for gambling losses to the amount of gambling winnings. It affects individuals and businesses engaged in wagering activities, such as sports betting or casino gambling. The key provision requires that losses from wagering transactions can only offset gains from those same transactions, eliminating deductions for excess losses. The rule applies to tax years beginning after December 31, 2025.
The GLOBE Act of 2025 is a comprehensive bill aimed at advancing LGBTQI rights globally through several key mechanisms. It requires U.S. diplomatic posts to document and respond to violence against LGBTQI people abroad, establishes sanctions against individuals responsible for human rights violations against LGBTQI people, and creates a Special Envoy for LGBTQI rights. The bill also reforms immigration policies to better protect LGBTQI refugees and asylum seekers, and expands U.S. foreign assistance to support LGBTQI rights organizations globally. These provisions directly affect LGBTQI individuals worldwide, U.S. diplomatic personnel, and organizations receiving U.S. foreign assistance.
S 2229, the United States Foreign Service Commemorative Coin Act, authorizes the minting of three commemorative coins to honor the 100th anniversary of the U.S. Foreign Service (established by the 1924 Rogers Act). It specifies $5 gold coins (max 50,000), $1 silver coins (max 400,000), and half-dollar coins (max 750,000) to be issued in 2029, featuring designs symbolizing U.S. diplomacy. A surcharge from each coin sale ($35 for gold, $10 for silver, $5 for half-dollar) will fund the Association for Diplomatic Studies and Training to preserve diplomatic history through oral histories and other programs. The coins are legal tender and will be sold at face value plus surcharge and production costs, with all funds going directly to support the Association's work.
This bill reauthorizes two existing federal diabetes programs through 2027. It provides $160 million annually for fiscal years 2026 and 2027 for the Special Diabetes Program for Type I Diabetes (serving people with Type I diabetes) and the Special Diabetes Program for Indians (serving Native American communities through Indian Health Services). A final $40 million is allocated for October-December 2027 for both programs, with all funds remaining available until expended. The bill extends current funding levels without changing program eligibility or structure.
S 2212, the VISIBLE Act, requires immigration enforcement officers to visibly display their agency name and either their last name or unique badge number during all public-facing immigration enforcement activities in the United States. This applies to officers from U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, and other authorized personnel during actions like stops, arrests, raids, or warrant service. The bill mandates that this identification be clearly legible from 25 feet away on outermost clothing, prohibits non-medical face coverings that obscure it (except in covert operations or hazardous conditions), and requires annual reports to Congress on compliance and disciplinary actions. It aims to increase transparency during immigration enforcement interactions where the public may be present.
This bill requires drug manufacturers to pay rebates to Medicare when their "selected drugs" (cancer and complex therapies subject to negotiated maximum fair prices) are used. Manufacturers must calculate rebates based on the difference between current Medicare payment rates (ASP+6) and new negotiated rates (MFP+6), covering the gap for beneficiaries. This lowers patient coinsurance from the current 20% of ASP+6 to 20% of MFP+6 for these specific drugs during the negotiated price period. The rebates are paid to the Medicare trust fund and apply to Medicare Part B beneficiaries using these drugs, directly affecting drug manufacturers and patients covered under Medicare Part B.
